Journal of Sleep Disorders & Therapy
Open Access

Navigating the Nexus: Insomnia and Psychotropic Medications

Maurice Caulet^{* *}Correspondence: Maurice Caulet, Department of Psychiatry and Behavioral Services, University of California, San Francisco, USA, Email:

Author info »

Description

Insomnia, a common sleep disorder characterized by difficulty falling asleep, staying asleep, or experiencing non-restorative sleep, is a multifaceted condition with a myriad of underlying causes and contributing factors. Among these, the use of psychotropic medications, including antidepressants, antipsychotics, and anxiolytics, represents a significant yet often overlooked contributor to insomnia. In this article, we explore the intricate relationship between insomnia and psychotropic medications, examining their impact on sleep quality, treatment considerations, and strategies for managing sleep disturbances in individuals receiving these medications.

Psychotropic medications play a important role in the management of various mental health conditions, including depression, anxiety disorders, bipolar disorder, and schizophrenia. However, many of these medications, particularly those that affect neurotransmitter systems such as serotonin, dopamine, and Gamma-Amino Butyric Acid (GABA), can disrupt the delicate balance of sleep-regulating mechanisms in the brain, leading to sleep disturbances and insomnia [1].

Antidepressants, such as Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), and Tri-Cyclic Antidepressants (TCAs), are commonly prescribed for the treatment of depression and anxiety disorders [2]. While these medications can alleviate symptoms of mood disorders and improve overall well-being, they are also associated with side effects that may impact sleep quality. Common side effects of antidepressants include insomnia, vivid dreams, nightmares, and changes in sleep architecture, such as decreased REM sleep and increased awakenings during the night [3].

Similarly, antipsychotic medications, used to manage psychotic symptoms in conditions like schizophrenia and bipolar disorder, may also disrupt sleep patterns. The sedating effects of firstgeneration antipsychotics (typical antipsychotics) can contribute to daytime drowsiness and lethargy, while the metabolic side effects of second-generation antipsychotics (atypical antipsychotics) [4], such as weight gain and metabolic syndrome, may indirectly affect sleep quality and increase the risk of sleep apnea [5]. Anxiolytic medications, including benzodiazepines and nonbenzodiazepine hypnotics, are commonly prescribed for the short-term management of anxiety and insomnia [6-8]. While these medications can induce sedation and promote sleep initiation, their long-term use is associated with tolerance, dependence, and rebound insomnia upon discontinuation. Moreover, benzodiazepines may disrupt sleep architecture, leading to fragmented sleep and impaired sleep quality, particularly in older adults.

The complex interplay between psychotropic medications and insomnia underscores the importance of individualized treatment approaches that consider the unique needs and circumstances of each patient. When prescribing psychotropic medications, healthcare providers should carefully assess the potential impact on sleep quality and consider strategies to mitigate sleep disturbances while maximizing therapeutic benefits.

One approach is to optimize the timing of medication administration to minimize disruptions to the sleep-wake cycle. For medications with sedating effects, such as certain antidepressants and antipsychotics, taking them in the evening or before bedtime may help promote sleep initiation and reduce daytime sedation. Conversely, medications that tend to be activating or stimulating, such as certain antidepressants, may be administered in the morning to minimize interference with sleep [9].

Additionally, adjunctive interventions, such as Cognitive- Behavioral Therapy for Insomnia (CBT-I), may be incorporated into treatment plans to address sleep disturbances and enhance sleep quality. CBT-I encompasses various techniques and strategies, including sleep hygiene education, stimulus control therapy, relaxation techniques, and sleep restriction therapy, aimed at modifying maladaptive sleep behaviors and promoting restorative sleep [10].

Furthermore, regular monitoring and follow-up are essential to assess the efficacy and tolerability of psychotropic medications and adjust treatment as needed. Open communication between patients and healthcare providers fosters collaboration and empowers individuals to voice concerns or difficulties related to sleep disturbances, facilitating timely intervention and support.

Conclusion

The relationship between insomnia and psychotropic medications underscores the complexities of managing sleep disturbances in individuals with mental health conditions. While these medications play a important role in alleviating symptoms and improving overall well-being, they may also contribute to sleep disruptions and compromise sleep quality. By adopting a holistic approach to treatment that integrates pharmacotherapy, adjunctive interventions, and regular monitoring, healthcare providers can optimize treatment outcomes and promote restorative sleep in individuals receiving psychotropic medications. Through collaborative efforts and customised interventions, we can navigate the nexus between insomnia and psychotropic medications to enhance the well-being and quality of life of those grappling with mental health challenges.

References

1. Plante DT. The evolving nexus of sleep and depression. Ame J Psychiatry. 2021;178(10):896-902.

   [Crossref] [GoogleScholar] [PubMed]

2. Tubbs AS, Fernandez FX, Ghani SB, Karp JF, Patel SI, Parthasarathy S, et al. Prescription medications for insomnia are associated with suicidal thoughts and behaviors in two nationally representative samples. J Clin Sleep Med. 2021;17(5):1025-1030.

   [Crossref] [GoogleScholar] [PubMed]

3. Grandner M, Olivieri A, Ahuja A, Büsser A, Freidank M, McCall WV. The burden of untreated insomnia disorder in a sample of 1 million adults: A cohort study. BMC Public Health. 2023;23(1):1481.

   [Crossref] [GoogleScholar] [PubMed]

4. Zhdanova IV, Wurtman RJ, Regan MM, Taylor JA, Shi JP, Leclair OU. Melatonin treatment for age-related insomnia. J Clin Endocrinol Metabo. 2001;86(10):4727-4730.

   [Crossref] [GoogleScholar] [PubMed]

5. Venner A, Todd WD, Fraigne J, Bowrey H, Eban-Rothschild A, Kaur S, et al. Newly identified sleep–wake and circadian circuits as potential therapeutic targets. Sleep. 2019;42(5):zsz023.

   [Crossref] [GoogleScholar] [PubMed]

6. Carrier F, Banayan D, Boley R, Karnik N. Ethical challenges in developing drugs for psychiatric disorders. Prog Neurobiol. 2017;152:58-69.

   [Crossref] [GoogleScholar] [PubMed]

7. Hong J, Park CH, Kim H, Hong Y, Ahn J, Jun JY, et al. Grief response of nursing professionals is associated with their depression, loneliness, insomnia, and work-related stress while working in COVID-19 inpatients wards. Psychiatry Investig. 2023;20(4):374.

   [Crossref] [GoogleScholar] [PubMed]

8. Lee J, Cho IK, Kim K, Kim C, Park CH, Yi K, et al. Discrepancy between desired time in bed and desired total sleep time, insomnia, depression, and dysfunctional beliefs about sleep among the general population. Psychiatry Investig. 2022;19(4):281.

   [Crossref] [GoogleScholar] [PubMed]

9. Suh S, Kim H, Dang-Vu TT, Joo E, Shin C. Cortical thinning and altered cortico-cortical structural covariance of the default mode network in patients with persistent insomnia symptoms. Sleep. 2016;39(1):161-171.

   [Crossref] [GoogleScholar] [PubMed]

10. Qi S, Zhang Y, Li X, Sun C, Ma X, Li S, et al. Improved functional organization in patients with primary insomnia after individually-targeted transcranial magnetic stimulation. Front Neurosci. 2022;16:859440.

    [Crossref] [GoogleScholar] [PubMed]